International R&D and Technology Transfer Agreements Negotiations and Conflict Management

Similar documents
Engaging Industry Partners

Merriann M. Panarella, Esq. Panarella Dispute Resolution Services P.O. Box Wellesley, MA

Rosatom Approach to IPR Management in Collaborative Projects on Innovations

Intellectual Property & Technology Transfer

EASY ACCESS IP AN INTRODUCTION FOR UTS RESEARCHERS FEBRUARY 2014 RESEARCH & INNOVATION OFFICE

A POLICY in REGARDS to INTELLECTUAL PROPERTY. OCTOBER UNIVERSITY for MODERN SCIENCES and ARTS (MSA)

INTELLECTUAL PROPERTY POLICY

Slide 15 The "social contract" implicit in the patent system

Identifying and Managing Joint Inventions

Workshop on International R&D and Technology Transfer Contracts Negotiations, Intellectual Property Rights and Dispute Resolution

Pharma - Biotech Collaborations: Optimizing Success, Minimizing Risk and Maintaining Alignment

IMI2 Intellectual Property rules in light of Call 10 topics. Magali Poinot, IMI Legal Manager IMI Stakeholder Forum 28 September 2016

Why patents DO matter to YOUR business

Change the Game, SMEs! Leverage on your IP

Arlindo Oliveira. An Intellectual Property Strategy supporting Open Innovation

Client s Statement of Rights & Responsibilities*

Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board

Hackathons as a Source of Entrepreneurship in Corporations

Preventing and Resolving Construction Disputes

Impact and Innovation in H2020 Proposals and projects

New York University University Policies

Guidelines for Facilitating the Use of Research Tool Patents in the Life Sciences. March 1, 2007 Council for Science and Technology Policy

World Trade Organization Regional Workshop, Hong Kong, November 11 to 13, 2014

Writing Killer Contracts (for yourself and your clients)

Innovation and Technology Law Curriculum

Practical Strategies for Biotechnology and Medical Device Companies to Manage Intellectual Property Rights

Accepting Equity When Licensing University Technology

Accepting Equity When Licensing University Technology

Patent Working Requirements Historical and Comparative Perspectives

COMPETITIVE INTELLIGENCE USING INTELLECTUAL PROPERTY INFORMATION

THE AMERICA INVENTS ACT NEW POST-ISSUANCE PATENT OFFICE PROCEEDINGS

Evolution of Research Consortia Increasing Clinical Focus

Strategic Imperative for Networking and Partnerships in Technology Transfer

Licensing, Transfer of Ownership and Dispute Resolution - Commercialization of Intellectual Property Generated in International R&D Projects

eskbook Emerging Life Sciences Companies second edition Chapter 8 Checklist for Planning and Conducting an Effective FTO Search

Herefordshire CCG Patient Choice and Resource Allocation Policy

Patents An Introduction for Owners

Technology transactions and outsourcing deals: a practitioner s perspective. Michel Jaccard

Continuing Healthcare Patient Choice and Resource Allocation Policy

Interactive Retainer Letter

PATENTS FOR CHEMICALS, PHARMACEUTICALS AND BIOTECHNOLOGY

COLLABORATIVE R&D & IP ISSUES IN TECHNOLOGY TRANSFER IN UNIVERSITY SYSTEM

NEW TREATY DEVELOPMENT AND HARMONIZATION OF INTELLECTUAL PROPERTY LAW

UNCITRAL Third International Colloquium on Secured Transactions Session on Contractual Guide on IP Licensing (Vienna, March 3, 2010)

Fact Sheet IP specificities in research for the benefit of SMEs

European Charter for Access to Research Infrastructures - DRAFT

FACULTY OF ENGINEERING & INFORMATION TECHNOLOGIES RESEARCH DATA MANAGEMENT PROVISIONS 2015

Litigators for Innovators

The Revised EU Block Exemption Regulation for Research and Development Agreements

Canada s Intellectual Property (IP) Strategy submission from Polytechnics Canada

COMMERCIALIZING AND INVESTING IN TECHNOLOGY:

INTERNATIONAL WINTER SCHOOL

19 Progressive Development of Protection Framework for Pharmaceutical Invention under the TRIPS Agreement Focusing on Patent Rights

Governing Council. Inventions Policy. October 30, 2013

Evaluating a Report of Invention & Licensing. Technology Development Boot Camp Peter Liao March 25, 2013

New ideas, new firms?

Lesli K. Johnson Licensed Psychologist Licensed Independent Social Worker 17 Blue Line Drive Athens, Ohio (740)

Policy Contents. Policy Information. Purpose and Summary. Scope. Published on Policies and Procedures (

Patents, Standards and the Global Economy

DOC-CAREERS II Project, Final conference Brussels 2012 University-Industry Intellectual property rights: Balancing interests

ESA Iris Programme Analysis & definition of the Satellite System Operations. Briefing 28 July

Protecting Intellectual Property under TRIPS, FTAs and BITs: Conflicting Regimes or Mutual Coherence?

TECHNOLOGY TRANSFER AT THE UNIVERSITY OF TENNESSEE: INVENTIONS AND COMMERCIALIZATION

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Jean W. Frydman Partner

Addenco ENERGY & COMMODITIES LAW FIRM. AddVANTE. ABOUT ADDENCO Who we are What we do Our clients Our group OUR SERVICES

Leader in Pharmaceutical Films

TRIPS, FTAs and BITs: Impact on Domestic IP- and Innovation Strategies in Developing Countries

Business Partnerships in Agriculture and Biotechnology that Advance Early-State Technology

Promoting European clean technologies in India & tackling climate change 1

Financing Growth Ventures to Minimize Equity Dilution

European Ground Systems Common Core

Policy 7.6 Intellectual Property Policy

CRS Report for Congress

David I. Greenbaum Partner

INTELLECTUAL PROPERTY (IP) SME SCOREBOARD 2016

INTELLECTUAL PROPERTY (IP) SME SCOREBOARD 2016

Intellectual Property

TRIPS Post Grant Flexibilities: Key Exceptions to Patent Holders' Rights. David Vivas Eugui

Support for Universities and R&D institutions

The 45 Adopted Recommendations under the WIPO Development Agenda

This contract is for services and products related to a photography shoot (hereafter Shoot ) to take place at the following time and place.

GUITAR PRO SOFTWARE END-USER LICENSE AGREEMENT (EULA)

BRAZILIAN PATENT SYSTEM SEMINAR Brazilian patent litigation and practical business. Marc Hargen Ehlers January 31, 2012

Intellectual Property Policy. DNDi POLICIES

Contents. 1 Introduction... 1

Protecting Your Trade Secrets in Silicon Valley and Beyond

Peer Mediation session for Stan and Susan 1999, 2014 by Debbie Dunn page 1

COMPETITIVE ADVANTAGES AND MANAGEMENT CHALLENGES. by C.B. Tatum, Professor of Civil Engineering Stanford University, Stanford, CA , USA

Technology Transfer Technology Transfer Office Research Committee Aristotle University of Thessaloniki

Paul E. Burns, Partner

Intellectual Property

TRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY ACCESS TO MEDICINE: Exploitation of pharmaceutical patents: compulsory licences SESSION 4

Upstream Petroleum Contracts, Accounting & Auditing Policies and Procedures

Virtual Mentor American Medical Association Journal of Ethics December 2006, Volume 8, Number 12:

Daryn A. Grossman. Proskauer.com. Partner. New York

Guidelines on Standardization and Patent Pool Arrangements

General Manager Assurance and Risk Management in Oakton;

Keywords: Synairgen plc, Southampton, collaboration, spin-out, asthma, COPD

Presentation to NAS Committee on IP Management in Standards-Setting Processes. Dan Bart President and CEO Valley View Corporation November 4, 2011

Transcription:

International R&D and Technology Transfer Agreements Negotiations and Conflict Management Dr. Claus-Joerg Ruetsch, Head Legal Diagnostics F. Hoffmann-La Roche Ltd Alicante March 11, 2011

Negotiations and Conflict Management Table of Contents 1 Background 2 Negotiation 3 Dispute Resolution 4 Summary

Background Innovative Healthcare Companies need numerous license agreements and collaborations in order to achieve/maintain a full product pipeline. Immunological Testing Blood Glucose Testing Key to such R&D collaboration and technology transfer agreements and thus subjects of later disagreements and disputes are the scope of the collaboration the rights of the respective partners the field(s) of application the financials the opportunity of one party to compete

International R&D and Technology Transfer Agreements Background In the pharmaceutical industry parties will typically go through an evaluation and allocation of tasks before development and clinical trials of product begin. Once successfully completed they lead to long-term manufacture or exploitation (marketing and sales) as long as patent protection exists. Regulatory requirements make swift changes difficult. Always long-term relationships Mostly of strategic importance Financial significance Complex multi-stage obligations of contract parties Clinical Chemistry Testing Amendments to agreed plans

Negotiation Shared development activities need to be planned and set forth clearly. Deliverables, timelines, process for change decisions Risky developments can lead to failure. Dispute clauses, steering committees Milestones help to monitor progress. Risk allocation through milestone structure, compensation for work done Exit provisions become more frequent. Transfer of work results, access to background technology

Negotiation Universities conduct active IP exploitation. New approach in recent years Negotiation of R&D Agreements is easier when the business models are understood (proprietary IP v. open IP). Agreement with competitor (same business model) can be easier than with university (different approach) Universities should upgrade the quality of the IP/Licensing department and internal interfaces. Not a part-time position Technology transfer should be encouraged as it is key for competitiveness. Filling the product pipeline is necessary and should result in a win-win situation

Dispute Resolution Facts In 2001 Roche and company X had entered into a co-development and supply agreement to develop an ISE Device for X s instrument. The product development yielded 6 prototypes and about 80 production instruments in 2002 and 2003, but X was not satisfied. Dispute over development steps and specifications arose and after many discussions the parties still had an insufficient development result. The unhappy contractual partner X sued Roche in a district court in Massachusetts.

Dispute Resolution Faced with the choice between a lengthy trial (estimated costs 1.5 Mio. USD) or mediation Roche took the initiative to propose mediation. The other side agreed to try mediation. Roche began preparations. These covered the contract history, financials, options, technology and opening briefs. The mediation on the day was shuttle mediation where the mediator moved back and forth between the parties. It took almost 13 hours to come to a solution. A payment to X was agreed and the dispute resolved.

Dispute Resolution Key Factors for Success in Dispute Resolution by Mediation Thorough preparation: fact finding on overall relationship fact finding on technical matters legal and financial risk analysis define goals Role of mediator Clear mandate for team at mediation Availability of back-up support

- Negotiations and Conflict Management Summary Collaboration, development, marketing or tech transfer agreements establish long-term relationships. Success depends on careful planning and follow through according to agreed R&D plan. If the parties anticipate problems during the negotiation or mediate their development difficulties early, the development can go on and the parties will most likely be successful. R&D contracts have to be specific and clear. Process for amendments needs to be defined. Any negotiated solution seems to be better than a one-time decision by an impartial third party. Template dispute resolution clauses encourage the use of mediation or alternative methods.

- Negotiations and Conflict Management Summary If the negotiated solution turns out to be lacking in some way, the parties are able to amend or to mediate a (new) solution. Disputes over R&D obligations or exploitation of license rights cannot linger on 4 6 years, which are sometimes necessary for a lawsuit. Mediation offers as expedited a solution as the parties require and a high degree of flexibility, e.g. mediation of one central question or mediation for a very limited time (with possibility to then find thereafter a solution without the mediator).

We Innovate Healthcare